RECBIO-B(02179): The China Securities Regulatory Commission issues a record filing notice regarding the company's full circulation plan for H shares.
Ruike Biotechnology-B (02179) announced that the company has recently received a filing notice from the China Securities Regulatory Commission regarding the date of January 13, 2026 for the full circulation of H shares to the company. According to the filing notice, the company has completed the filing with the China Securities Regulatory Commission for the conversion of a total of 142 million shares held by 28 shareholders into H shares. The filing notice is valid for 12 months from January 13, 2026. The company will apply to the Hong Kong Stock Exchange for approval for the listing and trading of the relevant H shares.
RECBIO-B(02179) Announcement: The company has recently received a notice from the China Securities Regulatory Commission regarding the record date for the full circulation of H shares to the company, which is January 13, 2026. According to the record notice, the company has completed the record with the China Securities Regulatory Commission for the conversion of a total of 142 million shares held by 28 shareholders into H shares. The record notice is valid for 12 months from January 13, 2026. The company will apply to the Hong Kong Stock Exchange for approval of the listing and trading of relevant H shares.
Related Articles
New Stock Preview | From "Deep Squatting" in Performance to Global Leapfrogging: Decoding the Breakthrough Logic of Sirio Pharma (300791.SZ)
From the sharp decline in the entrance to the "doji star", is the reversal of the low-stage consolidation of INNOGEN-B (02591) imminent?
New stock preview | Hujia Technology: Dual pressure of single brand and online dependence Can high-tech profit margins continue?
New Stock Preview | From "Deep Squatting" in Performance to Global Leapfrogging: Decoding the Breakthrough Logic of Sirio Pharma (300791.SZ)
From the sharp decline in the entrance to the "doji star", is the reversal of the low-stage consolidation of INNOGEN-B (02591) imminent?
New stock preview | Hujia Technology: Dual pressure of single brand and online dependence Can high-tech profit margins continue?
RECOMMEND
Multiple A‑Share Companies Update Hong Kong IPO Progress Since Start Of Year
30/01/2026
Mainland Pharmaceutical Companies Rush To Hong Kong, Over 10 Firms Queue For IPO
30/01/2026
2026 Hong Kong Market Faces Unlocking Peak: HKD 1.6 Trillion In Restricted Shares To Be Released, How Will The Market Respond?
30/01/2026
